Gnidimacrin

Gnidimacrin is a protein kinase C (PKC) activator. Gnidimacrin inhibits cell growth of human leukemias, stomach cancers and non-small cell lung cancers in vitro, and shows activity against murine leukemias and solid tumors in vivo. Gnidimacrin can be used for leukemias, stomach cancers and non-small cell lung cancers research[1].

Product Specifications

CAS Number

[60796-70-5]

UNSPSC

12352005

Target

PKC

Related Pathways

Epigenetics; TGF-beta/Smad

Field of Research

Cancer

Smiles

C(OC(=O)C1=CC=CC=C1)[C@H]2[C@@]34[C@]5([C@]6([C@](CO)(O6)[C@@H](O)[C@@]7(O)[C@]3([C@]([C@H](C)[C@@H]7OC(=O)C8=CC=CC=C8)([C@H](C)CCCCCC[C@@H](O)[C@@]9(O4)O[C@]5([C@](C(C)=C)(C2)O9)[H])[H])[H])[H])[H]

Molecular Formula

C44H54O12

Molecular Weight

774.90

References & Citations

[1]Yoshida M, et al. Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L. Int J Cancer. 1996 Apr 10;66 (2) :268-73.